Renal denervation offers a potentially transformative and minimally invasive option for treating hypertension. With this ...

In adults, a ≥10 mm difference in the lengths of the right and left kidneys on ultrasound is considered predictive of renal pathology. Khazaei et al. sought to determine a cutoff point at which ...

Boston Scientific (NYSE: BSX) announced today that it agreed to acquire intravascular ultrasound system developer SoniVie.

Regular screening, adhering to nutritional guidelines, and avoiding risky behaviors are the effective ways to keep kidneys ...

This patient proved to have diffuse metastatic renal cell carcinoma. Ultrasound of the liver shows a fluid-filled mass with a peripheral thin rim of viable tumor (arrows). This lesion was a ...

Boston Scientific is diving into the field of renal denervation, with a $540 million deal for SoniVie and its ...

Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire SoniVie Ltd., ...

Boston Scientific looks to catch up with Medtronic and Recor Medical in the much-hyped renal denervation space with its ...

The move aims to broaden interventional cardiology therapies with ultrasound-based renal denervation therapy to treat ...

The following is a summary of “Feasibility of a new L43K ultrasound probe attachment for intraoperative laparoscopic ultrasonography in robot-assisted partial nephrectomy,” published in the February ...

Boston Scientific (NYSE:BSX) has agreed to acquire medical device company SoniVie for around $360M upfront payment. As a ...